Prognostic versus predictive value of biomarkers in oncology

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

(2005) · The Lancet · doi:10.1016/s0140-6736(05)66544-0 · Cited by 7,553

Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework

(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762

A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer

Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Escudier, B., Eisen, T., Stadler, W. M., Szczylik, C., Oudard, S., Siebels, M., Negrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647

Diagnosis of gastrointestinal stromal tumors: A consensus approach

Fletcher, C. D. M., Berman, J. J., Corless, C., Gorstein, F., Lasota, J., Longley, B. J., Miettinen, M., O'Leary, T. J., Remotti, H., Rubin, B. P., et al. (2002) · Human Pathology · doi:10.1053/hupa.2002.123545 · Cited by 3,419

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,607

American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer

Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)

McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C., Van Glabbeke, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665

Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma

Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P., & Mazumdar, M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.289 · Cited by 1,576

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Smith, I., Procter, M., Gelber, R. D., Guillaume, S., Feyereislova, A., Dowsett, M., Goldhirsch, A., Untch, M., Mariani, G., Baselga, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60028-2 · Cited by 1,507

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer

Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

Eberhard, D. A., Johnson, B. E., Amler, L. C., Goddard, A. D., Heldens, S. L., Herbst, R. S., Ince, W. L., Jänne, P. A., Januario, T., Johnson, D. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.857 · Cited by 1,461

Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer

Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., Glas, A. M., Saghatchian d'Assignies, M., Bergh, J., Lidereau, R., Ellis, P., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj329 · Cited by 1,238

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125

Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer

Pérez-Soler, R., Chachoua, A., Hammond, L. A., Rowinsky, E. K., Huberman, M., Karp, D., Rigas, J., Clark, G. M., Santabárbara, P., & Bonomi, P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.057 · Cited by 1,070

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer

Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., Arribas, J., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk134 · Cited by 895

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours

Debiec-Rychter, M., Sciot, R., Le Cesne, A., Schlemmer, M., Hohenberger, P., van Oosterom, A. T., Blay, J.-Y., Leyvraz, S., Stul, M., Casali, P. G., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.030 · Cited by 892

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1964 · Cited by 872

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

Gusterson, B. A., Gelber, R. D., Goldhirsch, A., Price, K. N., Säve-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., & Reed, R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1049 · Cited by 838

Treatment of Early-Stage Breast Cancer

(1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03460030097037 · Cited by 782

Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers

Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H., Kemeny, N. E., Jessup, J. M., Locker, G. Y., Macdonald, J. S., Mennel, R. G., Norton, L., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1456 · Cited by 748

What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及ぼす効果を示した論文:無作為化比較試験のメタアナリシス

青儀, 健. (2006) · Mebio oncology · Cited by 683

Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions

Pao, W., & Miller, V. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.799 · Cited by 631

Molecular Predictors of Response to Epidermal Growth Factor Receptor Antagonists in Non–Small-Cell Lung Cancer

Sequist, L. V., Bell, D. W., Lynch, T. J., & Haber, D. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3585 · Cited by 624

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL

Wagner, K. W., Punnoose, E. A., Januario, T., Lawrence, D. A., Pitti, R. M., Lancaster, K., Lee, D., von Goetz, M., Yee, S. F., Totpal, K., et al. (2007) · Nature Medicine · doi:10.1038/nm1627 · Cited by 612

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., Haller, A., Lothaire, P., Meert, A.-P., Noel, S., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602258 · Cited by 605

HER-2/neu oncogene protein and prognosis in breast cancer.

Tandon, A. K., Clark, G. M., Chamness, G. C., Ullrich, A., & McGuire, W. L. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.1120 · Cited by 574

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Lenz, H.-J., Van Cutsem, E., Khambata-Ford, S., Mayer, R. J., Gold, P., Stella, P., Mirtsching, B., Cohn, A. L., Pippas, A. W., Azarnia, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7595 · Cited by 528

HER-2 gene amplification can be acquired as breast cancer progresses

Meng, S., Tripathy, D., Shete, S., Ashfaq, R., Haley, B., Perkins, S., Beitsch, P., Khan, A., Euhus, D., Osborne, C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402993101 · Cited by 508

Treatment of early-stage breast cancer

Hurd, T. C., Edge, S. B., Kahlenberg, M. S., Stomper, P. C., Proulx, G. M., Schwartz, G., Khatri, V., & Winston, J. S. (1999) · Current Problems in Cancer · doi:10.1016/s0147-0272(99)90004-1 · Cited by 477

Prognostic Value ofKITMutation Type, Mitotic Activity, and Histologic Subtype in Gastrointestinal Stromal Tumors

Singer, S., Rubin, B. P., Lux, M. L., Chen, C.-J., Demetri, G. D., Fletcher, C. D. �., & Fletcher, J. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.03.095 · Cited by 420

Quantitative Fluoroestradiol Positron Emission Tomography Imaging Predicts Response to Endocrine Treatment in Breast Cancer

Linden, H. M., Stekhova, S. A., Link, J. M., Gralow, J. R., Livingston, R. B., Ellis, G. K., Petra, P. H., Peterson, L. M., Schubert, E. K., Dunnwald, L. K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3810 · Cited by 394

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analyis based on 1,640 patients (pts)

Van Glabbeke, M. M., Owzar, K., Rankin, C., Simes, J., Crowley, J., & GIST Meta-analysis Group (MetaGIST) (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.10004 · Cited by 385

Multicenter Validation of a Gene Expression–Based Prognostic Signature in Lymph Node–Negative Primary Breast Cancer

Foekens, J. A., Atkins, D., Zhang, Y., Sweep, F. C. G. J., Harbeck, N., Paradiso, A., Cufer, T., Sieuwerts, A. M., Talantov, D., Span, P. N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.9115 · Cited by 361

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.

Kuukasjärvi, T., Kononen, J., Helin, H., Holli, K., & Isola, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2584 · Cited by 358

In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor Xenograft

Nagengast, W. B., de Vries, E. G., Hospers, G. A., Mulder, N. H., de Jong, J. R., Hollema, H., Brouwers, A. H., van Dongen, G. A., Perk, L. R., & Lub-de Hooge, M. N. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.041301 · Cited by 313

Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial

Van Cutsem, E., Nowacki, M., Lang, I., Cascinu, S., Shchepotin, I., Maurel, J., Rougier, P., Cunningham, D., Nippgen, J., & Köhne, C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4000 · Cited by 313

Indium-111–Labeled Trastuzumab Scintigraphy in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Perik, P. J., Lub-De Hooge, M. N., Gietema, J. A., van der Graaf, W. T. A., de Korte, M. A., Jonkman, S., Kosterink, J. G. W., van Veldhuisen, D. J., Sleijfer, D. T., Jager, P. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8448 · Cited by 310

Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites

Gancberg, D., Di Leo, A., Cardoso, F., Rouas, G., Pedrocchi, M., Paesmans, M., Verhest, A., Bernard-Marty, C., Piccart, M. J., & Larsimont, D. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf252 · Cited by 309

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

Zidan, J., Dashkovsky, I., Stayerman, C., Basher, W., Cozacov, C., & Hadary, A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602738 · Cited by 282

The Biology of Epidermal Growth Factor Receptor in Lung Cancer

Scagliotti, G. V., Selvaggi, G., Novello, S., & Hirsch, F. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-040007 · Cited by 270

Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.

Paterson, M. C., Dietrich, K. D., Danyluk, J., Paterson, A. H., LEES, A. W., Jamil, N. S. M., Hanson, J., Jenkins, H., Krause, B. E., & McBlain, W. A. (1991) · PubMed · Cited by 264

Follow-up study of HER-2/neu amplification in primary breast cancer.

Clark, G. M., & McGuire, W. L. (1991) · PubMed · Cited by 261

Hormone receptor status and survival in a population‐based cohort of patients with breast carcinoma

Grann, V. R., Troxel, A. B., Zojwalla, N. J., Jacobson, J. S., Hershman, D., & Neugut, A. I. (2005) · Cancer · doi:10.1002/cncr.21030 · Cited by 229

Predicting benefit from anti-angiogenic agents in malignancy

Jubb, A. M., Oates, A. J., Holden, S., & Koeppen, H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1946 · Cited by 228

Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas

Pham, D., Kris, M. G., Riely, G. J., Sarkaria, I. S., McDonough, T., Chuai, S., Venkatraman, E. S., Miller, V. A., Ladanyi, M., Pao, W., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3224 · Cited by 212

A Two-Gene Expression Ratio of Homeobox 13 and Interleukin-17B Receptor for Prediction of Recurrence and Survival in Women Receiving Adjuvant Tamoxifen

Goetz, M. P., Suman, V. J., Ingle, J. N., Nibbe, A. M., Visscher, D. W., Reynolds, C. A., Lingle, W. L., Erlander, M., Ma, X.-J., Sgroi, D. C., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1263 · Cited by 170

The clinical trail of TRAIL

Duiker, E. W., Mom, C. H., de Jong, S., Willemse, P. H. B., Gietema, J. A., van der Zee, A. G. J., & de Vries, E. G. E. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.018 · Cited by 166

Hypertension as a predictive factor of Sunitinib activity

Rixe, O., Billemont, B., & Izzedine, H. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm184 · Cited by 166

Linking oncogenic pathways with therapeutic opportunities

Bild, A. H., Potti, A., & Nevins, J. R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1976 · Cited by 163

Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma

Gong, Y., Booser, D. J., & Sneige, N. (2005) · Cancer · doi:10.1002/cncr.20987 · Cited by 158

Prognostic Significance of c-kit Mutation in Localized Gastrointestinal Stromal Tumors

Kim, T. W., Lee, H., Kang, Y., Choe, M. S., Ryu, M., Chang, H. M., Kim, J., Yook, J. H., Kim, B. S., & Lee, J. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0581 · Cited by 149

HOXB13-to-IL17BR Expression Ratio Is Related With Tumor Aggressiveness and Response to Tamoxifen of Recurrent Breast Cancer: A Retrospective Study

Jansen, M. P. H. M., Sieuwerts, A. M., Look, M. P., Ruigrok-Ritstier, K., Gelder, M. E. M., van Staveren, I. L., Klijn, J. G. M., Foekens, J. A., & Berns, E. M. J. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3676 · Cited by 129

Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data

Tejpar, S., Peeters, M., Humblet, Y., Gelderblom, H. A. J., Vermorken, J. B., Viret, F., Glimelius, B. L. G., Ciardiello, F., Kisker, O., & Cutsem, E. V. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4037 · Cited by 116

Comparison of Methods of Measuring HER-2 in Metastatic Breast Cancer Patients Treated With High-Dose Chemotherapy

Harris, L. N., Liotcheva, V. B., Broadwater, G., Ramirez, M. J., Maimonis, P. J., Anderson, S., Everett, T., Harpole, D. H., Moore, M. B., Berry, D. A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1698 · Cited by 96

Prognostic and Predictive Effects of Immunohistochemical Factors in High-Risk Primary Breast Cancer Patients

Kröger, N. M., Milde‐Langosch, K., Riethdorf, S., Schmoor, C., Schumacher, M. C., Zander, A. R., & Löning, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1340 · Cited by 90

Challenges for patient selection with VEGF inhibitors

Longo, R., & Gasparini, G. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0403-6 · Cited by 84

Tumor-derived Mutations in the TRAIL Receptor DR5 Inhibit TRAIL Signaling through the DR4 Receptor by Competing for Ligand Binding

Bin, L., Thorburn, J., Thomas, L. R., Clark, P. E., Humphreys, R. C., & Thorburn, A. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704210200 · Cited by 83

Targeting TRAIL Agonistic Receptors for Cancer Therapy

Carlo‐Stella, C., Lavazza, C., Locatelli, A., Viganò, L., Gianni, A. M., & Gianni, L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2774 · Cited by 72

Prognostic Significance of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand and Its Receptors in Adjuvantly Treated Stage III Colon Cancer Patients

van Geelen, C. M. M., Westra, J. L., de Vries, E. G. E., Ek, W. B., Zwart, N., Hollema, H., Boezen, H. M., Mulder, N. H., Plukker, J. T. M., de Jong, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8809 · Cited by 71

Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy

Wardelmann, E., Büttner, R., Merkelbach‐Bruse, S., & Schildhaus, H. (2007) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-007-0473-9 · Cited by 70

Improved Insight into Resistance Mechanisms to Imatinib in Gastrointestinal Stromal Tumors: A Basis for Novel Approaches and Individualization of Treatment

Sleijfer, S., Wiemer, E. A. C., Seynaeve, C., & Verweij, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-6-719 · Cited by 62

Targeting the epidermal growth factor receptor in metastatic colorectal cancer

Ng, K., & Zhu, A. X. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.09.006 · Cited by 42

3017 POSTER Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data from the EVEREST study

Humblet, Y., Peeters, M., Gelderblom, H. A. J., Vermorken, J. B., Viret, F., Glimelius, B. L. G., Ciardiello, F., Gallerani, E., Kisker, O., & Cutsem, E. V. (2007) · European Journal of Cancer Supplements · doi:10.1016/s1359-6349(07)70945-x · Cited by 16

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy

Bruni, D., Angell, H. K., & Galon, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0285-7 · Cited by 1,586

Network pharmacology: curing causal mechanisms instead of treating symptoms

Nogales, C., Mamdouh, Z. M., List, M., Kiel, C., Casas, A. I., & Schmidt, H. H. H. W. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.11.004 · Cited by 1,201

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

Linardou, H., Dahabreh, I. J., Kanaloupiti, D., Siannis, F., Bafaloukos, D., Kosmidis, P., Papadimitriou, C. A., & Murray, S. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70206-7 · Cited by 739

The Clinical Relevance of Cancer Cell Lines

Gillet, J.-P., Varma, S., & Gottesman, M. M. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt007 · Cited by 599

Biomarkers of response and resistance to antiangiogenic therapy

Jain, R. K., Duda, D. G., Willett, C. G., Sahani, D. V., Zhu, A. X., Loeffler, J. S., Batchelor, T. T., & Sorensen, A. G. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.63 · Cited by 572